Deep Dive: Deep Dive Into Reaching Eligible Patients for Sacubitril/Valsartan

In this segment, Dr. Muthiah Vaduganathan breaks down a recent study he led, which was published in JAMA Cardiology, examining the potential patient population and impact of optimal prescribing based on a label expansion from the FDA for Sacubitril/\Valsartan in February 2021.